Ollin Biosciences

Ollin Biosciences is a startup based in the United States. Brouky classifies it under Healthcare & Life Sciences.

Ollin Biosciences is a clinical-stage biotechnology company that acquires and develops therapies for vision-threatening conditions, including wet age-related macular degeneration (AMD) and diabetic macular edema (DME). According to investor materials, the company recently completed a Phase 2 study of a bispecific antibody targeting VEGF and Ang2 versus Vabysmo.